MA32621B1 - Traitement de maladie auto-immune et inflammatoire - Google Patents

Traitement de maladie auto-immune et inflammatoire

Info

Publication number
MA32621B1
MA32621B1 MA33682A MA33682A MA32621B1 MA 32621 B1 MA32621 B1 MA 32621B1 MA 33682 A MA33682 A MA 33682A MA 33682 A MA33682 A MA 33682A MA 32621 B1 MA32621 B1 MA 32621B1
Authority
MA
Morocco
Prior art keywords
autoimmune
treatment
inflammatory disease
biological activity
multiple sclerosis
Prior art date
Application number
MA33682A
Other languages
Arabic (ar)
English (en)
Inventor
Stewart Leung
Lixin Li
Xuebin Liu
Hongtao Lu
Ping Tsui
Jingwu Zang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA32621B1 publication Critical patent/MA32621B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux procédés de traitement de la sclérose en plaques et d'autres maladies auto-immunes ou troubles inflammatoires, et des antagonistes, comprenant des protéines de liaison isolées pour une utilisation dans les nouveaux procédés. La présente invention concerne en outre un procédé de traitement de la sclérose en plaques comprenant la neutralisation de l'activité biologique de il-7 par liaison à cd127 ou il-7. Les protéines de liaison isolées peuvent également neutraliser l'activité biologique de tslp.
MA33682A 2008-08-08 2011-03-08 Traitement de maladie auto-immune et inflammatoire MA32621B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8729408P 2008-08-08 2008-08-08
US16980109P 2009-04-16 2009-04-16
US21862709P 2009-06-19 2009-06-19
PCT/US2009/053136 WO2010017468A1 (fr) 2008-08-08 2009-08-07 Traitement de maladie auto-immune et inflammatoire

Publications (1)

Publication Number Publication Date
MA32621B1 true MA32621B1 (fr) 2011-09-01

Family

ID=41382165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33682A MA32621B1 (fr) 2008-08-08 2011-03-08 Traitement de maladie auto-immune et inflammatoire

Country Status (23)

Country Link
US (2) US20100040616A1 (fr)
EP (1) EP2318442A1 (fr)
JP (1) JP2011530533A (fr)
KR (1) KR20110044777A (fr)
CN (1) CN102177179A (fr)
AR (1) AR072985A1 (fr)
AU (1) AU2009279471A1 (fr)
BR (1) BRPI0916945A2 (fr)
CA (1) CA2733432A1 (fr)
CL (1) CL2011000269A1 (fr)
CO (1) CO6341640A2 (fr)
CR (1) CR20110118A (fr)
DO (1) DOP2011000041A (fr)
EA (1) EA201100150A1 (fr)
IL (1) IL211034A0 (fr)
MA (1) MA32621B1 (fr)
MX (1) MX2011001477A (fr)
NZ (1) NZ590994A (fr)
PE (1) PE20110382A1 (fr)
TW (1) TW201018482A (fr)
UY (1) UY32038A (fr)
WO (1) WO2010017468A1 (fr)
ZA (1) ZA201100974B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8171134B2 (en) * 2009-03-18 2012-05-01 At&T Intellectual Property I, L.P. Methods and apparatus to characterize and predict network health status
PE20170687A1 (es) * 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
AU2014201648B2 (en) * 2010-02-24 2016-05-12 Rinat Neuroscience Corp. Antagonist anti-il-7 receptor antibodies and methods
CA2801509A1 (fr) * 2010-06-02 2011-12-08 Dainippon Sumitomo Pharma Co., Ltd. Medicament de traitement pour des maladies auto-immunes et des maladies allergiques
US20130295111A1 (en) * 2010-08-10 2013-11-07 The Scripps Research Institute Methods and compositions for treating disorders associated with hyperactive immune system
EP3604339B1 (fr) 2011-01-14 2021-03-10 The Regents Of The University Of California Anticorps thérapeutiques contre la protéine ror-1 et leurs procédés d'utilisation
EP2583980A1 (fr) * 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
CN106456723B (zh) * 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
EP2955196A1 (fr) * 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
EP3194440A1 (fr) * 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
CN107073113A (zh) 2014-10-18 2017-08-18 辉瑞大药厂 抗il‑7r抗体组合物
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
WO2017055966A1 (fr) 2015-10-01 2017-04-06 Pfizer Inc. Compositions d'anticorps à faible viscosité
CA2997809A1 (fr) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps specifiques d'il-7r-alpha pour le traitement la leucemie lymphoblastique aigue
WO2017149394A1 (fr) 2016-02-29 2017-09-08 Ose Immunotherapeutics Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et son utilisation dans le traitement du cancer
JP6986559B2 (ja) 2016-12-09 2022-01-05 オセ イムノセラピューティクス Ｃｄ１２７に対して方向付けられた抗体及びポリペプチド
KR102666879B1 (ko) 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
CN111662381B (zh) * 2019-03-07 2022-06-07 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
PH12022551022A1 (en) 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
MX2022010012A (es) 2020-02-13 2022-09-07 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria.
EP4103605A1 (fr) 2020-02-13 2022-12-21 Amgen Inc. Traitement de la dermatite atopique avec un anticorps anti-tslp
IL295511A (en) 2020-02-18 2022-10-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of using them
JP2023551935A (ja) 2020-12-02 2023-12-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用
WO2023227641A1 (fr) 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Utilisation de protéines de liaison au tnf-alpha et de protéines de liaison à l'il-7 dans un traitement médical
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
EP4455308A1 (fr) 2023-04-24 2024-10-30 Les Laboratoires Servier Signatures géniques il-7r
EP4724504A1 (fr) * 2023-06-07 2026-04-15 FBD Biologics Limited Variants d'il-7 de synthèse et leurs procédés d'utilisation
WO2026062296A1 (fr) * 2024-09-23 2026-03-26 Ose Immunotherapeutics Thérapie par antagonisation d'l-7 ou cd127, et il-12, il-23, il-12r ou il-23r

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194375A (en) * 1989-06-15 1993-03-16 Immunex Corporation Dna encoding interleukin-7 receptors and methods of use
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0667395A4 (fr) * 1993-06-01 1996-07-03 Toray Industries Anticorps monoclonal, procede de production, et utilisation.
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
US20090130123A1 (en) * 2004-06-15 2009-05-21 Erol Fikrig Antibodies to west nile virus polypeptides
WO2006052660A2 (fr) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Blocage du recepteur il-7 pour supprimer l'immunite
GT200600065A (es) * 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
CA2513350A1 (fr) * 2005-03-02 2006-09-02 Sydney West Area Health Service Traitement contre la sclerose en plaques
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals

Also Published As

Publication number Publication date
ZA201100974B (en) 2012-10-31
US20100040616A1 (en) 2010-02-18
AU2009279471A1 (en) 2010-02-11
AR072985A1 (es) 2010-10-06
EP2318442A1 (fr) 2011-05-11
TW201018482A (en) 2010-05-16
CR20110118A (es) 2011-07-28
NZ590994A (en) 2012-09-28
PE20110382A1 (es) 2011-06-27
DOP2011000041A (es) 2011-02-28
KR20110044777A (ko) 2011-04-29
MX2011001477A (es) 2011-03-25
WO2010017468A1 (fr) 2010-02-11
CL2011000269A1 (es) 2012-07-20
BRPI0916945A2 (pt) 2015-11-24
US20110287000A1 (en) 2011-11-24
UY32038A (es) 2010-03-26
CO6341640A2 (es) 2011-11-21
CN102177179A (zh) 2011-09-07
EA201100150A1 (ru) 2011-10-31
IL211034A0 (en) 2011-04-28
JP2011530533A (ja) 2011-12-22
CA2733432A1 (fr) 2010-02-11

Similar Documents

Publication Publication Date Title
MA32621B1 (fr) Traitement de maladie auto-immune et inflammatoire
Xu et al. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
MY164376A (en) Phosphospecific antibodies recognizing tau
MA33717B1 (fr) Immunoconjugués ciblés
MA34738B1 (fr) Neutralisation d'anticorps anti-ccl20
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MX2011010353A (es) Composicion farmaceutica.
MA29836B1 (fr) Proteines de fusion avec l'albumine
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
PH12011502389B1 (en) Monoclonal antibody
DE60224879D1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
MX2010001111A (es) Mutantes mcp-1 que antagonizan glicosaminoglicano y metodos para utilizar los mismos.
WO2005112981A3 (fr) Compositions et methodes permettant de stimuler ou de renforcer l'osteoformation et l'autorenouvellement des cellules
RU2009140759A (ru) Бис-met-гистоны
BRPI0506890A (pt) derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo
EP1566387A3 (fr) Gènes impliqués dans la régulation de l'angiogenese, préparations pharmaceutiques les contenant et leurs applications
MA28969B1 (fr) Aptameres de liaison a la famille des cytokines de l'il-12 humaine et leur utilisation comme agents therapeutiques de maladies auto-immunes
MY149448A (en) Interleukin-21 receptor binding proteins
MA33199B1 (fr) Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques
EP2046394A4 (fr) Utilisation de séquences d'acide nucléique pour le traitement de maladies neurologiques et psychiatriques, vecteurs et compositions
EP2275547A3 (fr) Polynucléotides et séquences de polypeptide impliquées dans le procédé de remodelage des os
MA31664B1 (fr) Formulations orales de liberation commandee de composes de modulation de canal ionique et procedes associes pour prevenir l'arythmie